25 August 2016



ASX Announcement

Mach7 Technologies Awarded Second US Patent for Mobile Device Image Capture

- Second US Patent awarded covering any mobile device capturing images and video for use in a patient's electronic medical record
- Patented technology commercially available as Mach7 iModality

Melbourne, Australia; 25 August 2016: Mach7 Technologies Limited (**Mach7** or the **Company**) (ASX:**M7T**), a recognised leader in the enterprise imaging market, today announced that it has been awarded a second US Patent for medical image capture with a mobile device. The first US Patent awarded to the Company was previously announced on 13 January 2016.

The second United States Patent is described as Patent No. US 9,411,823 B1 "*Handheld Medical Imaging Mobile Modality*" and covers a method of acquiring medical imaging data via a mobile device and covers user authentication, medical image and video capture, association to the patient record, and secure wireless communication of image/video and metadata to a server. The method also includes a program for requesting, providing and transmitting medical image data from any mobile device.

The patented technology is commercially available in <u>Mach7 iModality</u>, Mach7's mobile image capture application. Mach7 iModality leverages the value of Mach7 Enterprise Imaging Platform by securely providing front-line clinicians and care providers with a superior mobile solution to capture and integrate photos, videos, sound files and notes and directly connect that data to the patient's electronic medical record. Mach7 iModality is accelerating mobile healthcare, enabling point of care delivery and optimising workflows for image producing specialties beyond radiology and cardiology.

About Mach7 Technologies:

Mach7 Technologies (ASX:M7T) develops innovative enterprise imaging IT solutions that create a clear and complete view of the patient to inform diagnosis, reduce care delivery delays and costs, and improve patient outcomes. Mach7's award-winning enterprise imaging platform provides a vendor neutral foundation for unstructured data consolidation and communication to power interoperability and enables healthcare enterprises to build their best-of-breed clinical ecosystems. Mach7's sophisticated workflow tools, advanced <u>clinical viewing</u> and optimised <u>vendor neutral archiving</u> solutions unlock silos of legacy systems empowering healthcare providers to own, access and share patient data without boundaries. Visit <u>www.mach7t.com</u>.

Mach7's wholly-owned subsidiary, 3D Medical Pty Ltd, provides medical specific 3D printing and is an exclusive distributor of various synergistic technologies including holographic projection. 3D Medical's innovative products leverage data already captured by conventional imaging modalities and apply it in more meaningful ways to deliver improved economic and patient outcomes. Visit <u>www.3dmedical.com.au/</u>



ASX Announcement

25 August 2016

Contacts:

Albert Liong CEO +1 650 743 0167 (U.S.) albert.liong@mach7t.com Jenni Pilcher CEO Australia, CFO +61 3 9646 2222 (Australia) jenni.pilcher@mach7t.com Julia Vaughn Investor Relations (U.S.) +1 802 768 0143 (U.S.) julia.vaughn@mach7t.com